Impact of midfoot and Hindfoot involvement on functional disability in Korean patients with rheumatoid arthritis

Hye-Jin Jeong1, Il Woong Sohn2, Dam Kim2, Soo-Kyung Cho2, Si-Bog Park3, Il-Hoon Sung4 and Yoon-Kyoung Sung2*

Abstract

Background: Foot involvement in rheumatoid arthritis (RA) patients has been reported to severely affect functional capacity and quality of life. We aimed to determine the impact of midfoot and hindfoot involvement on functional disability in Korean patients with RA.

Methods: We evaluated the RA involvement and deformity of three regions of the foot (forefoot, midfoot and hindfoot) and ankle using conventional radiography in Korean patients with RA. We compared the clinical features between RA patients with and without foot or ankle involvement. Using multivariable logistic regression analyses, the impact of midfoot or hindfoot involvement on functional disability in RA patients was evaluated.

Results: Overall, 120 patients with a median age of 48.0 (interquartile range, 37–56) years and median disease duration of 58.0 (IQR, 10–89) months were included. The prevalence of foot or ankle RA involvement was 74 (61.7%). The number of patients with forefoot, midfoot, hindfoot and ankle involvement was 32 (43.2%), 24 (32.4%), 46 (62.2%) and 4 (5.4%), respectively. Compared to patients without foot or ankle involvement those with such involvement had greater disease activity and functional disability, more of them were treated with biologic agents, and they had a lower health-related quality of life. After adjusting for potential confounders, hindfoot involvement was associated with a higher degree of functional disability. However, walking difficulty was more associated with midfoot involvement rather than with involvement in other regions.

Conclusions: In Korean patients with RA, hindfoot involvement is associated with functional disability and midfoot involvement affects walking.

Keywords: Functional disability, Health assessment questionnaire-disability index, Hindfoot, Midfoot, Rheumatoid arthritis

Background

Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects multiple joints, especially the small joints of the hands and feet [1, 2]. Chronic joint inflammation results in synovial thickening, the production of excessive joint fluid, and damage to cartilage and bones, which can lead to permanent joint destruction and disability [1]. It is thought that in the early stages of the disease joint inflammation affects daily functioning mainly due to pain and swelling, while in later stages of the disease joint destruction and deformity increase functional impairment [3].

Foot involvement is a major cause of disability in RA [4], and can lead to a deterioration in daily activity and quality of life [5, 6]. Approximately 80–90% of patients with RA experience foot pain during the course of the disease [1, 5, 7, 8]. Yet, despite the large number of RA patients with foot complaints, these are frequently overlooked when caring for patients with multiple joint pains and deformities. For example, the disease activity score (DAS)-28 is the most widely used assessment tool of disease activity in RA, but the joints in the foot are not included in the 28-joint count [9]. Even patients in a remission state may suffer from foot pain [10, 11].
The foot is divided into three regions (the forefoot, midfoot and hindfoot). The forefoot is composed of the metatarsal bones and the phalanges connected by the metatarsophalangeal (MTP) and interphalangeal (IP) joints. The forefoot acts as a lever during the pressing phase of the gait. Forefoot deformity is characterized by hallux valgus and subluxation of the MTP joints [6]. The foot impairment caused by RA most commonly affects the forefoot, and symptoms begin in the MTP joints in most cases [5, 8, 12]. The midfoot joint, including naviculocuneiform joint and tarsometatarsal (TMT) joint, constitutes the longitudinal arch of the foot and allows the load to be transferred to the forefoot during gait [12, 13]. Additional functions provided by the midfoot are the ability to walk on uneven ground and to absorb shock [7]. The midfoot is not commonly affected on its own but is involved in 40–60% of patients with RA [6, 12]. The hindfoot joint, including the talonavicular, calcaneocuboid and talocalcaneal (also known as subtalar) joints, performs the side-to-side motion of the foot and provides stability at the initiation of the foot strike and is involved in 30–60% of RA cases [6, 12, 14]. It is also less frequently involved in the absence of midtarsal- and MTP joint disease. The ankle permits two types of movement, dorsiflexion and plantar flexion and contributes to lower limb stability [14]. The ankle joint is less commonly involved than other joints of the foot. RA involvement of the ankle joint is seen in approximately 9–26% of patients [4, 14, 15].

Numerous studies have reported an association between RA involvement or deformity of the forefoot in RA and functional disability [16–21]. In those cases, orthotic devices and surgical treatment are able to relieve pain and improve function [14]. However, there are a few studies on the effects of midfoot- and hindfoot arthritis in RA [15, 22, 23]. The purpose of the present study was to assess the prevalence of midfoot and hindfoot involvement and its impact on functional disability in Korean patients with RA.

Methods
Study population
A total of 120 RA patients were included in this study. It used baseline data from published research on the impact of patient education on the satisfaction of Korean patients with RA in a rheumatology clinic of a tertiary referral hospital [24]. According to the protocol of this previous study, 120 patients were classified into 3 groups; 40 biologic disease-modifying antirheumatic drug (DMARD) users of any disease duration, 40 conventional DMARD users of less than 2 years of disease duration, and 40 conventional DMARD users with over 2 years of disease duration. All patients were over 18 years of age and fulfilled either the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) or the 1987 ACR classification criteria for RA. Patients with a diabetic foot ulcer, peripheral vascular disease, peripheral neuropathy, or foot fracture and previous surgery on the foot were excluded. All the patients voluntarily completed a consent form and the study was approved by Hanyang University Hospital Institutional Review Board (IRB No. 2014–08-023 & No. 2015–03-008).

Data collection
Participants were interviewed face-to-face and also filled out self-completed questionnaires. Demographic data (age, sex) and clinical data (duration of disease, medications such as glucocorticoid, conventional and biological DMARD) were evaluated by face-to-face interview. We calculated the body mass index (BMI) (calculated as weight in kilograms divided by the square of height in meters) by measuring height and weight. Participants were examined the number of swollen/tender joints, patient’s global assessment on visual analog scale by interview. Laboratory data included C-reactive protein (CRP), ESR, and presence of rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (ACPA) were collected. Disease activity was measured using the disease activity score 28 - erythrocyte sedimentation rate (DAS28-ESR) [9]. The Korean version of the EuroQol five-dimension questionnaire (EQ-5D), a tool for assessing quality of life, was evaluated by self-completed questionnaires [25].

Radiologic measurement of RA involvement and deformity of the foot and ankle
All radiographic data were collected within one year of the enrollment date. Supine anteroposterior and weight-bearing lateral views of conventional radiographs of both feet were obtained for all subjects. Radiographs of both feet together were obtained in anteroposterior view, and radiographs of the individual feet were obtained separately in lateral view. These radiographs were independently assessed by two rheumatologists. In cases of discrepancies in the readings of the two examiners, the radiograph was inspected again and discussed until a consensus was reached. We evaluated RA involvement in three parts of the foot (forefoot, midfoot and hindfoot) and the ankle joint; the forefoot joint included the first to fifth MTP joints and the first IP joint; the midfoot joint included the first to fifth TMT joints (also known as the Lisfranc joint) and the naviculocuneiform joint; the hindfoot joint consisted of the talonavicular, calcaneocuboid and talocalcaneal joint; the ankle joint included tibiotalar joint. RA involvement was defined as the presence of erosion on least one side or a unilateral or bilateral joint space-narrowing. For example, the presence of erosion or joint space narrowing in either the
unilateral or bilateral first-to-fifth MTP and first IP joint allowed a patient to be classed as having forefoot RA involvement. The same method also applied to midfoot, hindfoot and ankle RA involvement. We also investigated foot deformities, such as hallux valgus, metatarsus primus varus, splayfoot and pes planus. Hallux valgus was defined as a greater than 20° angle of intersection between the longitudinal axis of the first metatarsal and the proximal phalanx. Metatarsus primus varus was defined as a greater than 10° angle of intersection between the first and second metatarsal. Splayfoot was defined as a greater than 35° intermetatarsal angle between the first and fifth metatarsal. Pes planus was defined as less than 20° of calcaneal pitch, which is the angle between the lower surface of the calcaneus and the ground.

**Functional disability as an outcome**

Functional disability was evaluated using the Korean version of the Health Assessment Questionnaire-Disability Index (HAQ-DI) [26]. The disability index comprises 20 questions classified into eight categories, including dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. Each question is rated on a scale ranging from 0 (no difficulty) to 3 (unable to do). The score of HAQ-DI is the mean of the eight category scores.

**Statistical analysis**

Inter- and intraobserver agreement was calculated using prevalence-adjusted and bias-adjusted kappa [27]. We compared the clinical features, including HAQ-DI scores, of RA patients with and without the presence of a foot or ankle RA involvement. The chi-square test was used to compare categorical data and the Mann-Whitney U-test was used to compare continuous data between pairs of groups. Then we performed univariable and multivariable logistic regression analyses to find the impact of midfoot and hindfoot RA involvement on functional disability (HAQ-DI ≥ 0.5 as a median) and walking disability (walking score, which is a subcategory of HAQ-DI, ≥ 1). Variables significant in the univariable analysis at some arbitrary level (P < 0.25) and potential predictors of HAQ-DI (age, disease duration) and foot involvement (BMI, sites of RA involvement) were selected as candidates for the multivariable analysis. All data was analyzed using SPSS for Windows Version 18.0 (SPSS Inc., Chicago, IL, USA) and P-values less than 0.05 were considered statistically significant.

**Results**

The results for inter- and intraobserver agreement are shown in Additional file 1: Table S1.

**Baseline characteristics and prevalence of foot involvement**

A total of 120 patients (113 females, 7 males) with a median age of 48.0 years [interquartile range (IQR), 37–56 years] were included in this study. The median disease duration was 58.0 months (IQR, 10–89 months). Seventy-four patients (61.7%) had a foot or ankle RA involvement in at least one region. Among these, the prevalence of forefoot, midfoot, hindfoot and ankle involvement was 32 (43.2%), 24 (32.4%), 46 (62.2%) and 4 (5.4%), respectively.

The demographic and clinical characteristics of all patients, both with and without foot or ankle involvement, are outlined in Table 1. The group with foot or ankle involvement had higher median visual analogue scale (VAS) scores (30.0 vs. 15.0, p < 0.05) and higher median DAS28-ESR scores (4.08 vs. 3.07, p < 0.05) than the group without foot or ankle involvement. From the medication histories, only biologic DMARDs were used significantly more often in the foot or ankle involvement group (44.6% vs. 15.2%, p < 0.05). Also, health-related quality of life, as assessed by the EQ-5D, was lower in the group with foot or ankle involvement (0.76 vs. 0.81, p < 0.05).

**Foot involvement and functional disability**

The distribution of RA joint involvement is shown in Fig. 1 and median HAQ-DI scores according to the locus of RA involvement are shown in Fig. 2. The median HAQ-DI score was higher in the group with foot or ankle involvement than in the non-involvement group (0.63 vs. 0.38, p < 0.05). Patients with midfoot involvement had the highest HAQ-DI score, followed by hindfoot involvement.

**Impact of midfoot involvement and hindfoot involvement on functional disability**

In univariable analysis, midfoot involvement corresponded with a 4.68-fold increase and hindfoot involvement corresponded with a 4.66-fold increase in the risk of being in the higher functional disability group (HAQ-DI score ≥ 0.5 as a median) (Table 2). After adjusting for age, disease duration, BMI, RF positivity, glucocorticoid use, biologic DMARD use, and foot deformities, DAS28-ESR [odds ratio (OR) 4.33, 95% confidence interval (CI) 1.69–11.1, p < 0.05] and hindfoot involvement (OR 3.14, 95% CI 1.18–8.38, p < 0.05) were risk factors for functional disability (Table 2). Additionally, DAS28-ESR (OR 6.88, 95% CI 1.84–25.7, p < 0.05), glucocorticoid use (OR 8.24, 95% CI 1.77–38.4, p < 0.05) and midfoot involvement (OR 5.81, 95% CI 1.41–23.9, p < 0.05) were risk factors affecting walking disability (walking score in HAQ-DI ≥ 1) after adjusting for other clinical variables and foot deformities (Table 3).
The aim of this study was to assess the prevalence of midfoot and hindfoot involvement, and its effect on functional disability in Korean patients with RA. Hindfoot involvement was most common, and midfoot involvement was as common as forefoot involvement. Foot involvement was associated with poor quality of life and functional disability. Of the various groups, those with midfoot involvement had the greatest functional disability, and hindfoot involvement and midfoot involvement were risk factors for functional disability and walking disability, respectively.

We found that a total of 61.7% of patients had foot or ankle RA involvement, which is a somewhat lower prevalence than in previous reports; the reported prevalence rates of RA foot or ankle involvement have varied from 64% to 96.2% [5–7, 28]. The reasons for our lower prevalence are that our patients were relatively young, their disease was of short duration, and many were receiving biological agents. It has been previously reported that the forefoot is most commonly affected in RA [2, 4, 5, 7]. In a previous report, the prevalences of forefoot, midfoot, hindfoot and ankle radiographic involvement in RA were 88%, 62%, 32% and 26%, respectively.

### Table 1 Comparison of baseline characteristics between patients with and without foot or ankle RA involvement

| Variables                        | No RA involvement in the foot or ankle, n = 46 | RA involvement in the foot or ankle, n = 74 | P value |
|----------------------------------|------------------------------------------------|------------------------------------------|---------|
| Age, median (IQR), years         | 45.5 (36.8–54.0)                               | 50.5 (38.75–58.0)                        | 0.09    |
| Disease duration, median (IQR), months | 47.5 (7.50–80.0)                              | 63.0 (12.3–103.3)                        | 0.09    |
| BMI, median (IQR), kg/m²         | 21.7 (20.5–24.0)                               | 22.9 (20.2–25.0)                         | 0.35    |
| Patient global assessment, VAS (0–10), median (IQR) | 15.0 (10.0–30.0)                              | 30.0 (10.0–40.0)                         | <0.05   |
| CRP, median (IQR), mg/dl         | 0.40 (0.34–0.95)                               | 0.40 (0.15–1.13)                         | 0.97    |
| ESR, median (IQR), mm/h          | 18.5 (10.0–40.0)                               | 27.0 (11.8–43.0)                         | 0.35    |
| DAS28-ESR, median (IQR)          | 3.07 (2.50–4.10)                               | 4.08 (3.05–5.07)                         | <0.05   |
| Female, n (%)                    | 45 (97.8)                                     | 68 (91.9)                                | 0.25    |
| RF positive, n (%)               | 39 (84.8)                                     | 65 (87.8)                                | 0.63    |
| ACPA positive, n (%)             | 42 (91.3)                                     | 65 (89.0)                                | 0.86    |
| Medications, n (%)               |                                               |                                          |         |
| Glucocorticoid                   | 35 (76.1)                                     | 54 (73.0)                                | 0.71    |
| NSAID                            | 38 (82.6)                                     | 67 (90.5)                                | 0.20    |
| Methotrexate                     | 44 (95.7)                                     | 67 (90.5)                                | 0.48    |
| Conventional DMARDs⁴             | 45 (97.8)                                     | 72 (97.3)                                | 1.00    |
| Biologic DMARDs⁵                 | 7 (15.2)                                      | 33 (44.6)                                | <0.05   |
| EQ-5D, median (IQR)              | 0.81 (0.75–0.86)                              | 0.76 (0.69–0.84)                         | <0.05   |
| HAQ-DI (0–3), median (IQR)       | 0.38 (0–0.5)                                  | 0.63 (0.13–1.16)                         | <0.05   |
| RA involvement, n (%)            |                                               |                                          |         |
| Forefoot                         | 0                                             | 32 (43.2)                                | NA      |
| Midfoot                          | 0                                             | 24 (32.4)                                | NA      |
| Hindfoot                         | 0                                             | 46 (62.2)                                | NA      |
| Ankle                            | 0                                             | 4 (5.4)                                  | NA      |
| Foot deformity, n (%)            |                                               |                                          |         |
| Hallux valgus                    | 8 (17.4)                                      | 18 (24.3)                                | 0.37    |
| Metatarsus primus varus          | 16 (34.8)                                     | 22 (29.7)                                | 0.56    |
| Splayfoot                        | 0                                             | 2 (2.7)                                  | 0.52    |
| Pes planus                       | 43 (93.5)                                     | 71 (95.9)                                | 0.67    |

ACPA anti-cyclic citrullinated protein antibody, BMI body mass index, CRP C-reactive protein, DAS28 disease activity score 28, DMARDs disease-modifying antirheumatic drugs, ESR erythrocyte sedimentation rate, EQ-5D EuroQol five-dimension questionnaire, HAQ-DI Health Assessment Questionnaire-Disability Index, IQR interquartile range, NA not applicable, NSAID non-steroidal anti-inflammatory drug, RF rheumatoid factor, SD standard deviation, VAS visual analogue scale

⁴Conventional DMARDs include methotrexate, hydroxychloroquine, sulfasalazine and leflunomide

⁵Biologic DMARDs include adalimumab, etanercept, golimumab, abatacept and rituximab
respectively [4]. However, hindfoot involvement was most common and midfoot RA involvement was as common as forefoot involvement in our study. The difference in the order of frequency of involvement according to location is probably due to differences in definition. Since the reported extent and degree of involvement of foot joints varies greatly between studies, a consensus definition may be required to permit reliable comparisons between studies, cross-sectional design.

In a previous report, foot and ankle joint destruction was divided into 5 clusters: normal, forefoot, midfoot, mid-hindfoot and combined type. Of these, the mid-hindfoot and combined type deformities showed a significant change in functional disability and decrease in walking ability [6]. Although a slightly different definition of foot involvement was used, the midfoot and hindfoot involvement groups also had greater functional disability in our study. In addition, midfoot involvement and hindfoot involvement were risk factors for walking disability and total functional disability in this study. Therefore, midfoot and hindfoot arthritis is likely to be important for the function and activity levels of RA patients.

A previous study showed that longer disease duration is associated with impaired foot function and reduced walking speed in patients with RA-related foot complaints because of alterations in pressure distribution and gait patterns [29]. Another study reported a correlation between disease duration and hallux rigidus and claw toe, which are typical forefoot deformities [7]. Also, the incidence rate of the pes planus, which is a common midfoot deformity, increases with longer disease duration in RA patients [30]. Consistently, our study found that median disease duration was significantly longer in the foot or ankle involvement group than in the non-involvement group.

High BMI was correlated with foot problems in some previous studies [2, 28] because excessive mechanical load has an effect on joint damage. However, we found no significant difference in BMI between RA patients.

Fig. 1 The distribution of RA joint involvement

Fig. 2 Median Health Assessment Questionnaire (HAQ) scores according to RA involvement in the foot or ankle.
Table 3 Factors influencing walking disability (walking score of HAQ-DI ≥ 1) in patients with RA (n = 120)

| Variables            | Unadjusted analysis | Adjusted analysis |
|----------------------|---------------------|-------------------|
|                      | OR (95% CI)         | P value           | OR (95% CI)         | P value           |
| Age                  | 1.00 (0.97–1.03)    | 0.87              | 1.01 (0.97–1.05)    | 0.78              |
| Disease durationa    | 2.25 (1.02–4.99)    | 0.05              | 1.85 (0.59–5.86)    | 0.29              |
| BMI                  | 1.05 (0.95–1.16)    | 0.37              | 1.03 (0.90–1.17)    | 0.71              |
| DAS28-ESRb           | 6.34 (2.79–14.40)   | <0.05             | 4.33 (1.69–11.10)   | <0.05             |
| RF positive          | 2.67 (0.87–8.22)    | 0.09              | 2.34 (0.64–8.64)    | 0.20              |
| Glucocorticoid       | 1.70 (0.74–3.88)    | 0.21              | 2.00 (0.67–6.58)    | 0.19              |
| Biologic DMARDs      | 3.76 (1.65–8.56)    | 0.00              | 1.58 (0.51–4.92)    | 0.43              |
| RA involvement       |                     |                   |                   |                   |
| Forefoot             | 0.91 (0.41–2.05)    | 0.83              | 1.03 (0.39–2.71)    | 0.95              |
| Midfoot              | 4.68 (1.62–13.60)   | <0.05             | 2.02 (0.49–8.29)    | 0.33              |
| Hindfoot             | 4.66 (2.07–10.5)    | <0.05             | 3.14 (1.18–8.38)    | <0.05             |
| Ankle                | 0.93 (0.13–6.85)    | 0.95              | 0.68 (0.06–7.70)    | 0.75              |
| Foot deformity       |                     |                   |                   |                   |
| Hallux valgus        | 1.67 (0.69–4.06)    | 0.26              | 1.03 (0.32–3.33)    | 0.96              |
| Metatarsus primus varus | 1.06 (0.49–2.29)   | 0.89              | 1.09 (0.41–2.88)    | 0.87              |
| Pes planus           | 2.22 (0.39–12.60)   | 0.37              | 1.30 (0.15–10.90)   | 0.81              |

BMI body mass index, DAS28 disease activity score 28, DMARDs disease-modifying antirheumatic drugs, ESR erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire-Disability Index, OR odds ratio, RF rheumatoid factor

aDisease duration was divided into two groups based on a cut-off of 2 years

bDAS28-ESR was divided into two groups, remission to low disease activity (DAS28-ESR ≤ 3.2) and moderate to high disease activity (DAS28-ESR > 3.2)

---

Table 3 Factors influencing walking disability (walking score of HAQ-DI ≥ 1) in patients with RA (n = 120)

| Variables            | Unadjusted analysis | Adjusted analysis |
|----------------------|---------------------|-------------------|
|                      | OR (95% CI)         | P value           | OR (95% CI)         | P value           |
| Age                  | 1.00 (0.97–1.03)    | 0.99              | 1.01 (0.97–1.06)    | 0.56              |
| Disease durationa    | 2.28 (0.93–5.59)    | 0.07              | 1.81 (0.48–6.85)    | 0.39              |
| BMI                  | 1.08 (0.97–1.20)    | 0.15              | 1.07 (0.93–1.24)    | 0.34              |
| DAS28-ESRb           | 10.5 (3.40–32.11)   | <0.05             | 6.88 (1.84–25.7)    | <0.05             |
| RF positive          | 2.39 (0.64–8.94)    | 0.19              | 1.82 (0.40–8.37)    | 0.44              |
| Glucocorticoid       | 4.59 (1.48–14.2)    | <0.05             | 8.24 (1.77–38.4)    | <0.05             |
| Biologic DMARDs      | 4.21 (1.86–9.51)    | <0.05             | 1.89 (0.54–6.64)    | 0.32              |
| RA involvement       |                     |                   |                   |                   |
| Forefoot             | 0.72 (0.30–1.75)    | 0.47              | 0.85 (0.28–2.60)    | 0.77              |
| Midfoot              | 6.00 (2.28–15.8)    | <0.05             | 5.81 (1.41–23.9)    | <0.05             |
| Hindfoot             | 2.85 (1.30–6.25)    | <0.05             | 1.24 (0.41–3.76)    | 0.71              |
| Ankle                | 0.66 (0.07–6.54)    | 0.72              | 0.29 (0.02–5.73)    | 0.42              |
| Foot deformity       |                     |                   |                   |                   |
| Hallux valgus        | 1.33 (0.54–3.28)    | 0.53              | 0.68 (0.19–2.51)    | 0.56              |
| Metatarsus primus varus | 0.89 (0.39–2.03)   | 0.78              | 0.93 (0.30–2.85)    | 0.90              |
| Pes planus           | 1.00 (0.18–5.71)    | 1.00              | 0.50 (0.05–5.22)    | 0.56              |

BMI body mass index, DAS28 disease activity score 28, DMARDs disease-modifying antirheumatic drugs, ESR erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire-Disability Index, OR odds ratio, RF rheumatoid factor

aDisease duration was divided into two groups based on a cut-off of 2 years

bDAS28-ESR was divided into two groups, remission to low disease activity (DAS28-ESR ≤ 3.2) and moderate to high disease activity (DAS28-ESR > 3.2)
with foot or ankle involvement and without involvement. In addition, BMI was not associated with functional disability.

Over the last decades, treatment for RA has become more aggressive with the advent of biologic DMARDs. One-third of our patients were treated with biologic DMARDs and a higher proportion of patients those with foot or ankle involvement used biologic DMARDs. This result is consistent with other reports [19, 31].

A previous study found that damage in the midfoot occurs suddenly and peaks in cases 5–10 years after RA diagnosis. After that period, midfoot injury rates decrease, while mid-hind foot type injuries gradually increase [6]. In another study, hindfoot involvement was rarely observed in the absence of midtarsal and MTP joint disease [4]. These results support the hypothesis that midfoot involvement may precede hindfoot involvement. Although our results do not support that hypothesis, if it is correct early intervention for patients with midfoot arthritis could prevent hindfoot impairment and rescue functional capacity.

In RA patients with foot arthritis, medical and surgical treatment options are available to decrease pain and improve function. First, it is important to educate patients on how to carefully inspect their feet carefully and about the necessity of need for regular exercise, which is helpful to stretch tendons, strengthen muscles and maintain maximum range of motion [14]. Then, we can provide pain relief and resolve joint inflammation through pharmacologic treatments. Orthotic devices, such as shoes, canes and crutches, are useful in ambulation and can provide support to the arch, accommodate a deformed foot and relieve pain. Surgical treatment, including synovectomy and reconstruction, are also helpful in cases of severe inflammation and progressive joint destruction [8, 12, 13, 32]. Our study highlights the importance of focusing on midfoot and hindfoot problems, and not exclusively forefoot problems, in routine clinical care with physical and radiographic examination for early detection and treatment.

There are a few limitations to our study. First, it had a cross-sectional design and involved a relatively small number of patients. Second, we could not evaluate additional radiographic views such as foot oblique and ankle AP view for more accurate assessment. Third, we could not use quantitative radiographic scoring methods such as the Sharp/van der Heijde Score or Larsen score. Because these scoring system focus on foot deformity rather than midfoot or hindfoot deformity. And we lacked information about current treatments for foot arthritis in terms of the use of orthoses, footwear and steroid injection. However, because more than half of the patients had some degree of foot involvement, we were able to use a multivariable model to identify whether foot involvement was a risk factor for functional impairment. Our study is also meaningful in that it is the first study to assess the impact of foot involvement in the three foot sub-sections on functional disability in Korean RA patients. The present study highlights the importance for early detection of focusing on midfoot and hindfoot problems in routine clinical care, together with physical and radiographic examination, rather than exclusively on forefoot problems. Early detection of foot involvement can reduce disability through early treatment. This study may guide a future longitudinal study designed to evaluate how progression of foot involvement impacts on the outcomes of RA patients using radiographic assessment tools that distinguish between RA and osteoarthritis foot involvement.

Conclusions

Although the foot is not examined in the clinical assessment of disease activity in RA, foot abnormalities are seen frequently and may affect disability in RA. In particular, hindfoot involvement is associated with functional disability and midfoot involvement affects walking. Foot involvement remains a great problem even though a large number of patient with RA are now being treated with biological agents. We suggest that foot involvement should be regularly monitored in order to reduce the functional disability of RA patients.

Additional file

Additional file 1: Table S1. Interobserver and intraobserver agreement for assessment of radiographs. (DOCX 16 kb)

Abbreviations

ACPA: Anti-cyclic citrullinated peptide antibody; ACR: American College of Rheumatology; BMI: Body mass index; CI: Confidence interval; CRP: C-reactive protein; DAS: Disease activity score; DMARDs: Disease-modifying antirheumatic drugs; EQ-SD: EuroQol five-dimension questionnaire; ESR: Erythrocyte sedimentation rate; EULAR: European League Against Rheumatism; HAQ-DI: Health Assessment Questionnaire-Disability Index; IP: Interphalangeal; IQR: Interquartile range; MTP: Metatarsophalangeal; OR: Odds ratio; PARAK: prevalence-adjusted and bias-adjusted Kappa; RA: Rheumatoid arthritis; RF: Rheumatoid factor; TMT: Tarsometatarsal; VAS: Visual analogue scale

Acknowledgments

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI16C0273).

Funding

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI16C0273).

Availability of data and materials

All data generated or analysed during this study are included in this published article.
Authors’ contributions

HIJ and IWS collected and analyzed clinical and sonographic data. DK contributed to the analysis and interpretation of data. SKC, SBF, and IHS gave valuable advice and comments regarding this. YRS participated in the design of the study. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by the institutional review board of the Hanyang University Hospital (HYUH IRB 2015-03-008). All participants provided written informed consent.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Department of Rheumatology, Keimyung University Dongsan Medical Center, Daegu, South Korea. 2Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea. 3Department of Rehabilitation Medicine, Hanyang University Hospital, Seoul, South Korea. 4Department of Orthopedic Surgery, Hanyang University Hospital, Seoul, South Korea.

Received: 23 February 2017 Accepted: 15 August 2017

Published online: 24 August 2017

References

1. van der Leeden M, Steultjens M, Dekker JH, Prins AP, Dekker J. Forefoot joint damage, pain and disability in rheumatoid arthritis patients with foot complaints: the role of plantar pressure and gait characteristics. Rheumatology (Oxford). 2006;45(4):465–9.
2. Otter SJ, Lucas K, Springett K, Moore A, Davies K, Young A, et al. Comparison of foot pain and foot care among rheumatoid arthritis patients taking and not taking anti-TNFα therapy: an epidemiological study. Rheumatol Int. 2010;31(11):1515–9.
3. Hamamoto Y, Ito H, Funu M, Hashimoto M, Fuji T, Ishikawa M, et al. Serological and progression differences of joint destruction in the wrist and the feet in rheumatoid arthritis - a cross-sectional cohort study. PloS One. 2015;10(8):e0136611.
4. Vidigal E, Jacoby RK, Doon AS, Ratliff AH, Kirkup J. The foot in chronic rheumatoid arthritis. Ann Rheum Dis. 1975;34(4):292–7.
5. Rojas-Villarraga A, Bayona J, Zuluaga N, Mejía S, Hincapié ME, Anaya JM. The impact of rheumatoid foot on disability in Colombian patients with rheumatoid arthritis. BMC Musculoskeletal Disord. 2009;10:67.
6. Matsumoto T, Nakamura I, Miura A, Momoyama G, Ito K. Radiologic pattern of joint damage to the foot in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011;66(4):499–507.
7. Bal A, Aydog E, Aydog ST, Cakci A. Foot deformities in rheumatoid arthritis and relevance of foot function index. Clin Rheumatol. 2006;25(5):671–5.
8. Hellwell P, Siddle H, Redmond A. The foot and ankle in rheumatology. Arthritis Res. 2011;13(8):1–11.
9. Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van der Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44–8.
10. Landewe R, van der Heijde D, van der Linden S, Boers M. Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. Ann Rheum Dis. 2006;65(5):637–41.
11. Wechalekar MD, Lester S, Proudman SM, Cleland LG, Whittle SL, Rischmueler M, et al. Active foot synovitis in patients with rheumatoid arthritis: applying clinical criteria for disease activity and remission may result in understestimation of foot joint involvement. Arthritis Rheum. 2012;65(5):1316–22.
12. Patel A, Rao S, Nawozenski D, Flemister AS, DiGiovanni B, Baumhauer JF. Midfoot arthritis. J Am Acad Orthop Surg. 2010;18(7):417–25.
13. Verhoeven N, Vandevenne G. Midfoot arthritis: diagnosis and treatment. Foot Ankle Surg. 2012;18(4):255–62.
14. VABoo R, Iorio L. Rheumatoid arthritis of the foot and ankle. J Am Acad Orthop Surg. 1994;2(6):326–33.
15. Chan PS, Kong KO. Natural history and imaging of subtalar and midfoot joint disease in rheumatoid arthritis. Int J Rheum Dis. 2013;16(1):14–8.
16. Keenan MA, Peabody TD, Gronley JK, Perry J. Valgus deformities of the feet and characteristics of gait in patients who have rheumatoid arthritis. J Bone and Joint Surg Am. 1991;73(2):237–47.
17. Mann RA, Horton GA. Management of the foot and ankle in rheumatoid arthritis. Rheum Dis Clin N Am. 1996;22(3):457–76.
18. Jaakola J, Mann RA. A review of rheumatoid arthritis affecting the foot and ankle. Foot Ankle Int. 2004;25(12):866–74.
19. Grondal L, Tengstrand B, Nordmark B, Wretenberg P, Stark A. The foot: still the most important reason for walking incapacity in rheumatoid arthritis: distribution of symptomatic joints in 1,000 RA patients. Acta Orthop. 2008;79(2):57–61.
20. van der Leeden M, Steultjens MP, Urum J, Dahmen R, Roorda LD, Schaardenburg DV, et al. Prevalence and course of forefoot impairments and walking disability in the first eight years of rheumatoid arthritis. Arthritis Rheum. 2006;55(11):1596–602.
21. Otter SJ, Lucas K, Springett K, Moore A, Davies K, Cheek L, et al. Foot pain in rheumatoid arthritis prevalence, risk factors and management: an epidemiological study. Clin Rheumatol. 2010;29(3):255–71.
22. Only NE, Breusch SJ. Additive hindfoot arthrodesis for rheumatoid hindfoot disease: a clinical study of patient outcomes and satisfaction. Clin Rheumatol. 2013;32(12):2177–82.
23. Cracchio A 3rd. Rheumatoid arthritis. Hindfoot disease. Clin Orthop Relat Res. 1997;34058–68.
24. Soo-Kyung C, Dam K, Jeongin C, Seung L, Ga Eun B, Hyeon Kyung K, et al. Impact of patient education on the satisfaction of rheumatoid arthritis patients: a randomized trial of nurse-led versus medical Doctor-led education. J Rheum Dis. 2016;23(2):109–17.
25. Kim M-H, Cho YS, Uhm W-S, Kim S, Baе S-C. Cross-cultural adaptation and validation of the Korean version of the EQ-SD in patients with rheumatic diseases. Qual Life Res. 2005;14(5):1401–6.
26. Bae SC, Cook EF, Kim SY. Psychometric evaluation of a Korean health assessment questionnaire for clinical research. J Rheumatol. 1998;25(10):1975–9.
27. Bytt T, Bishop J, Carlin JB. Bias, prevalence and kappa. J Clin Epidemiol. 1993;46(5):423–9.
28. Borman P, Auyhan F, Tuncay F, Sahin M. Foot problems in a group of patients with rheumatoid arthritis: an unmet need for foot care. Open Rheumatol J. 2012;6:290–5.
29. van der Leeden M, Steultjens M, Dekker JH, Prins AP, Dekker J. The relationship of disease duration to foot function, pain and disability in rheumatoid arthritis patients with foot complaints. Clin Exp Rheumatol. 2007;25(2):275–80.
30. Bouysset M, Tebib J, Noel E, Taveneir T, Miossec P, Vianey JC, et al. Rheumatoid flat foot and deformity of the first ray. J Rheumatol. 2002;29(5):1035–53.
31. Otter SJ, Lucas K, Springett K, Moore A, Davies K, Young A, et al. Comparison of foot pain and foot care among rheumatoid arthritis patients taking and not taking anti-TNFα therapy: an epidemiological study. Rheumatol Int. 2011;31(11):1515–9.